{
  "id": "5e499c636d0a27794100000a",
  "type": "factoid",
  "question": "What is molecular radiotherapy?",
  "ideal_answer": "Molecular radiotherapy is working through tumor-targeted radionuclides.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28747518",
    "http://www.ncbi.nlm.nih.gov/pubmed/29043399"
  ],
  "snippets": [
    {
      "text": "Molecular radiotherapy with tumor-targeted radionuclides may overcome some of these challenges",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28747518",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Neuroblastoma may be treated with molecular radiotherapy, 131I meta-Iodobenzylguanidine and 177Lu Lutetium DOTATATE, directed at distinct molecular targets: Noradrenaline Transporter Molecule (NAT) and Somatostatin Receptor (SSTR2), respectively. This study used immunohistochemistry to evaluate target expression in archival neuroblastoma tissue, to determine whether it might facilitate clinical use of molecular radiotherapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29043399",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Molecular radiotherapy is working through tumor-targeted radionuclides."
}